Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?

Biotech institution Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% implicit the past 12 months. Cathie Wood’s ARK accrued its involvement successful the institution by 8% successful the 4th quarter, entering 2026 with a $10.5 cardinal position.

Crispr Therapeutics Ag (NASDAQ:CRSP) has the first-mover vantage successful the cistron editing and cistron therapy industries with its CRISPR-based attraction approved by the FDA. Its CASGEVY therapy for terrible sickle compartment illness and beta-thalassemia is already generating gross done its concern with Vertex. Crispr Therapeutics Ag (NASDAQ:CRSP) has a beardown pipeline and an precocious exertion to edit cells some extracurricular the body.

Crispr Therapeutics Ag (NASDAQ:CRSP) saw an summation successful hedge money sentiment successful the 4th quarter, arsenic 32 funds ended the 4th with the banal successful their portfolios, up from 31 funds successful the anterior quarter.

Contrarius Global Equity Fund stated the pursuing regarding CRISPR Therapeutics AG (NASDAQ:CRSP) successful its third 4th 2025 capitalist letter:

“In December 2023, aft astir 6 years of quality objective trials, the FDA approved the archetypal CRISPR-Cas9 cistron editing therapy. This therapy is CRISPR Therapeutics AG’s (NASDAQ:CRSP) attraction for sickle compartment disease. Sickle compartment illness (SCD) is simply a debilitating hereditary humor upset that results successful periods of excruciating symptom and yet a beingness expectancy that is much than 20 years beneath the average. CRSP’s therapy, called Casgevy, knocks retired the BCL11A gene, the cistron liable for suppression of foetal haemoglobin (HbF). With the gene’s enactment disrupted, the assemblage begins producing HbF connected its ain again. HbF people prevents sickle compartment complications, providing a functional cure. Sickle compartment illness occurs successful astir 1 retired of each 365 Black oregon African American births and astir 1 retired of each 16,300 Hispanic American births. CRSP has partnered with Vertex Pharmaceuticals, a overmuch larger pharmaceutical company, to assistance successful commercialisation and distribution. Casgevy is not cheap, astatine astir $2.2 cardinal per usage currently, but it should beryllium a ‘one-and done’ treatment, and compares favourably to the beingness interaction from reduced healthcare costs from illness flare-ups (estimated to beryllium betwixt $4 cardinal and $6 million). As portion of the concern with Vertex, CRSP retains 40% of profits worldwide. A perchance immense marketplace accidental fixed the estimation of 100,000 SCD sufferers successful the US alone. Vertex appears to agree, it paid astir $900 cardinal upfront, and a further $200 cardinal astatine FDA support successful bid to summation their involvement from 50% to 60%…” (Click present to work the afloat text)